RxDoctor Payments Data

Larry Ferdinand, MD

Ophthalmology · Ocean Springs, MSNPI 1255599601

Payments from drug & device makers

What this record shows

11 manufacturers reported payments, led by Alcon at 42.4% of the total. 2025 is the largest year on record at $1,766, more than ten times the $105 reported in 2019.

$3,960in general payments, 2019–2025

Across 35 payments — averaging $113.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Bausch & Lomb Americas Inc.$1K
  • Glaukos Corporation$156
  • Sun Pharmaceutical Industries Inc.$150
  • Genentech USA, Inc.$146
  • Johnson & Johnson Surgical Vision, Inc.$145
  • plus $293 from 5 others

What the payments were for

  • Travel & lodging$2,17355%
  • Food & beverage$1,78745%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,960 in reported general payments places this provider in the 75th percentile of 150 ophthalmology providers in Mississippi.

See all ophthalmology providers in Mississippi

Medicare billing

Part B allowed, 2024
$141,033
Medicare patients
586
Services billed
1,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine11$15,186
Prednisolone Acetate140$4,550
Ketorolac Tromethamine109$2,623
MoxifloxacinMoxifloxacin Hcl92$2,606
Latanoprost67$547
Brimonidine Tartrate30$530
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat29$255
ErythromycinErythromycin Base16$179
Doxycycline Hyclate17$158
Timolol Maleate13$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$137$15,18611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 150 ophthalmology providers in Mississippi.

Other ophthalmology in Ocean Springs

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →